CN Patent

CN114630667A — 用于治疗癌症的vs-6063与ch5126766的组合

Assigned to CANCER RESEARCH INSTITUTE · Expires 2022-06-14 · 4y expired

What this patent protects

本发明涉及的方法包括将FAK抑制剂(例如，VS‑6063)与RAF/MEK双重抑制剂(例如，CH5 126766)组合施用，用于治疗受试者(例如人类)的异常细胞生长，例如癌症。

USPTO Abstract

本发明涉及的方法包括将FAK抑制剂(例如，VS‑6063)与RAF/MEK双重抑制剂(例如，CH5 126766)组合施用，用于治疗受试者(例如人类)的异常细胞生长，例如癌症。

Drugs covered by this patent

Patent Metadata

Patent number: CN114630667A
Jurisdiction: CN
Classification: —
Expires: 2022-06-14
Drug substance claim: No
Drug product claim: No
Assignee: CANCER RESEARCH INSTITUTE
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.